|
| Exchange Disseminated Time | Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on
February 12, 2015 to consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2014 (Q3).
Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window shall remain closed for Directors and other designated employees of the Company from January 30, 2015 to February 13, 2015 (both days inclusive) for the purpose of approval of Unaudited Financial Statements for the Third Quarter ended December 31, 2014. |
|
|